An interventional study of In-person VExUS Training Program and Remote VExUS Training Program in Acute Heart Failure (AHF), Fluid Over-load and Congestion, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Diagnostic
This randomized controlled trial evaluates the effectiveness of two training approaches (in-person versus remote) for teaching medical residents to apply the Venous Excess Ultrasound (VExUS) score for bedside volume assessment in patients with acute heart failure. Resident performance will be compared to that of expert physicians certified in abdominal and duplex sonography.
Accurate assessment of volume status is essential in managing acute heart failure but remains challenging in clinical practice. The VExUS score is a validated ultrasound-based tool integrating inferior vena cava diameter and Doppler assessment of hepatic, portal, and intrarenal veins.
This single-center randomized controlled trial compares two training modalities (in-person vs. remote) in medical residents with basic ultrasound skills. Participants will be randomized 1:1 to either training method and compared to a control group of expert physicians.
Primary outcomes include ultrasound image quality assessed using a standardized 100-point score. Secondary outcomes include time to acquisition, VExUS scoring accuracy, self-confidence, and acceptability of training methods.
98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.
This study's planned enrollment of 23 is below the median of 68 across 51 interventional studies indexed under Hyperemia.
Browse Hyperemia studies →Insel Gruppe AG, University Hospital Bern is the lead sponsor of 741 studies on the registry; 180 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1-hour theoretical introduction 3-hour supervised practical ultrasound session Group-based hands-on training with expert coach
Behavioral: In-person VExUS Training Program
E-learning theoretical module 20 independently performed ultrasound exams Asynchronous expert feedback (phone/email)
Behavioral: Remote VExUS Training Program
SGUM-certified physicians performing VExUS examinations
Other: No intervention
In-person training consisting of a 1-hour theoretical introduction followed by a 3-hour supervised hands-on ultrasound training session focusing on acquisition and interpretation of the VExUS score.
Remote training consisting of an e-learning module followed by independently performed ultrasound examinations with asynchronous expert feedback (via phone or email).
SGUM-certified physicians performing VExUS examinations as expert reference standard.
Ultrasound Image Quality Score
The primary outcome will be a quality score, adapted from a quality score used in a previous randomized controlled trial which investigated a simulator-based training program for transoesophageal echocardiography.11 The quality score will include items commonly used for assessment of ultrasound quality: angle and depth, overall clarity, visualization of the anatomical structures, focus, doppler gain, scale and baseline resulting in a maximum achievable quality score of 100 points. If multiple images of the predefined views are captured, each image will be rated, and the best rating will be kept to calculate the final score. If a view is missing, 0 point will be awarded for that view. All ultrasound images will be independently assessed by experts for abdominal sonography and use Doppler sonography in their daily clinical practice and are blinded to the role (resident vs. SGUM-certified physician) and training (in-person vs. remote) program of the participants.
Time frame: From training until 6 months after completion of training
Time for Image Acquisition and Interpretation
Time required by participants to perform the ultrasound examination and interpret the images during VExUS assessment
Time frame: From training until 6 months after completion of training
Change in self-confidence in performing VExUS assessment
Self-reported confidence measured using a Likert-scale questionnaire before and after training
Time frame: From baseline (before training) to immediately after completion of training
Acceptability of the program (quantitative assessment)
Acceptability of the program will be assessed using a structured survey with 5-point Likert scale items based on an implementation framework (e.g., Theoretical Domains Framework). Results will be reported as mean scores or median values on a 5-point scale, where higher scores indicate greater acceptability.
Time frame: Immediately after completion of training and during the outcome assessment period (within 2 months after training)
VEXUS score
The Venous Excess Ultrasound Score (VExUS) is a semi-quantitative ultrasound-based score used to assess systemic venous congestion by combining inferior vena cava (IVC) diameter and Doppler flow patterns of abdominal veins, including hepatic, portal, and intrarenal veins. The score ranges from 0 to 3, with 0 indicating no congestion, 1 indicating mild congestion, 2 indicating moderate congestion, and 3 indicating severe venous congestion. Higher scores indicate greater venous congestion and worse clinical status.
Time frame: From training until 6 months after completion of training
Acceptability of the program (qualitative assessment)
Acceptability, including perceived barriers and facilitators to implementation, will be explored through semi-structured interviews. Data will be analyzed using thematic analysis guided by an implementation framework.
Time frame: Immediately after completion of training and during the outcome assessment period (within 2 months after training)
Plan to share: Yes
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →